The saga of JAK2 mutations and translocations in hematologic disorders

pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms

Cristina A. Smith, Guang Fan

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

JAK2 is a tyrosine kinase involved in cytokine signaling. The JAK2V617F point mutation, first described in 2005, results in constitutive activation of JAK2 and is now widely used as a diagnostic marker for Philadelphia chromosome negative myeloproliferative neoplasms. In recent years, more novel JAK2 mutations and fusion genes have been discovered in myeloproliferative neoplasms and other hematologic malignancies. This review aims to summarize the discovery and use of the JAK2V617F point mutation, other novel JAK2 mutations, and JAK2 translocations in diagnosing myeloproliferative neoplasms, acute myeloid leukemia, and acute lymphoid leukemia. JAK2 mutation testing is addressed, including the sensitivity and specificity of the different JAK2 mutation testing methods, clinical indications for use, and the use of quantitative JAK2 mutation testing for routine pathologic diagnosis, prognosis, and monitoring response to therapy. The relationship of JAK2 mutation to endogenous erythroid colony formation, thrombopoietin receptor mutation, polycythemia rubra vera-1 overexpression, and thrombopoietin receptor underexpression in myeloproliferative neoplasms are explored. Also discussed are the JAK2 inhibitors for clinical trials. Finally, the advantages of the newly proposed World Health Organization classification for myeloproliferative neoplasms are reviewed.

Original languageEnglish (US)
Pages (from-to)795-810
Number of pages16
JournalHuman Pathology
Volume39
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Mutation
Thrombopoietin Receptors
Neoplasms
Point Mutation
Therapeutics
Philadelphia Chromosome
Polycythemia Vera
Gene Fusion
Hematologic Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Clinical Trials
Cytokines
Sensitivity and Specificity

Keywords

  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Chronic myeloproliferative disorder
  • JAK2 mutation
  • JAK2 translocation
  • Lymphoma
  • Myelodysplastic syndrome
  • Myeloproliferative neoplasms
  • WHO classification

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{2332b884a7224e22a2bdbf0b6d493b1f,
title = "The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms",
abstract = "JAK2 is a tyrosine kinase involved in cytokine signaling. The JAK2V617F point mutation, first described in 2005, results in constitutive activation of JAK2 and is now widely used as a diagnostic marker for Philadelphia chromosome negative myeloproliferative neoplasms. In recent years, more novel JAK2 mutations and fusion genes have been discovered in myeloproliferative neoplasms and other hematologic malignancies. This review aims to summarize the discovery and use of the JAK2V617F point mutation, other novel JAK2 mutations, and JAK2 translocations in diagnosing myeloproliferative neoplasms, acute myeloid leukemia, and acute lymphoid leukemia. JAK2 mutation testing is addressed, including the sensitivity and specificity of the different JAK2 mutation testing methods, clinical indications for use, and the use of quantitative JAK2 mutation testing for routine pathologic diagnosis, prognosis, and monitoring response to therapy. The relationship of JAK2 mutation to endogenous erythroid colony formation, thrombopoietin receptor mutation, polycythemia rubra vera-1 overexpression, and thrombopoietin receptor underexpression in myeloproliferative neoplasms are explored. Also discussed are the JAK2 inhibitors for clinical trials. Finally, the advantages of the newly proposed World Health Organization classification for myeloproliferative neoplasms are reviewed.",
keywords = "Acute lymphoblastic leukemia, Acute myeloid leukemia, Chronic myeloproliferative disorder, JAK2 mutation, JAK2 translocation, Lymphoma, Myelodysplastic syndrome, Myeloproliferative neoplasms, WHO classification",
author = "Smith, {Cristina A.} and Guang Fan",
year = "2008",
month = "6",
doi = "10.1016/j.humpath.2008.02.004",
language = "English (US)",
volume = "39",
pages = "795--810",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - The saga of JAK2 mutations and translocations in hematologic disorders

T2 - pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms

AU - Smith, Cristina A.

AU - Fan, Guang

PY - 2008/6

Y1 - 2008/6

N2 - JAK2 is a tyrosine kinase involved in cytokine signaling. The JAK2V617F point mutation, first described in 2005, results in constitutive activation of JAK2 and is now widely used as a diagnostic marker for Philadelphia chromosome negative myeloproliferative neoplasms. In recent years, more novel JAK2 mutations and fusion genes have been discovered in myeloproliferative neoplasms and other hematologic malignancies. This review aims to summarize the discovery and use of the JAK2V617F point mutation, other novel JAK2 mutations, and JAK2 translocations in diagnosing myeloproliferative neoplasms, acute myeloid leukemia, and acute lymphoid leukemia. JAK2 mutation testing is addressed, including the sensitivity and specificity of the different JAK2 mutation testing methods, clinical indications for use, and the use of quantitative JAK2 mutation testing for routine pathologic diagnosis, prognosis, and monitoring response to therapy. The relationship of JAK2 mutation to endogenous erythroid colony formation, thrombopoietin receptor mutation, polycythemia rubra vera-1 overexpression, and thrombopoietin receptor underexpression in myeloproliferative neoplasms are explored. Also discussed are the JAK2 inhibitors for clinical trials. Finally, the advantages of the newly proposed World Health Organization classification for myeloproliferative neoplasms are reviewed.

AB - JAK2 is a tyrosine kinase involved in cytokine signaling. The JAK2V617F point mutation, first described in 2005, results in constitutive activation of JAK2 and is now widely used as a diagnostic marker for Philadelphia chromosome negative myeloproliferative neoplasms. In recent years, more novel JAK2 mutations and fusion genes have been discovered in myeloproliferative neoplasms and other hematologic malignancies. This review aims to summarize the discovery and use of the JAK2V617F point mutation, other novel JAK2 mutations, and JAK2 translocations in diagnosing myeloproliferative neoplasms, acute myeloid leukemia, and acute lymphoid leukemia. JAK2 mutation testing is addressed, including the sensitivity and specificity of the different JAK2 mutation testing methods, clinical indications for use, and the use of quantitative JAK2 mutation testing for routine pathologic diagnosis, prognosis, and monitoring response to therapy. The relationship of JAK2 mutation to endogenous erythroid colony formation, thrombopoietin receptor mutation, polycythemia rubra vera-1 overexpression, and thrombopoietin receptor underexpression in myeloproliferative neoplasms are explored. Also discussed are the JAK2 inhibitors for clinical trials. Finally, the advantages of the newly proposed World Health Organization classification for myeloproliferative neoplasms are reviewed.

KW - Acute lymphoblastic leukemia

KW - Acute myeloid leukemia

KW - Chronic myeloproliferative disorder

KW - JAK2 mutation

KW - JAK2 translocation

KW - Lymphoma

KW - Myelodysplastic syndrome

KW - Myeloproliferative neoplasms

KW - WHO classification

UR - http://www.scopus.com/inward/record.url?scp=44449118424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449118424&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2008.02.004

DO - 10.1016/j.humpath.2008.02.004

M3 - Article

VL - 39

SP - 795

EP - 810

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -